NCT02355028View on ClinicalTrials.gov

LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration

PHASE2CompletedINTERVENTIONAL

Enrollment

136

Participants

Timeline

Start Date

March 3, 2015

Primary Completion Date

September 15, 2016

Study Completion Date

October 18, 2016

Conditions

Exudative Age-Related Macular Degeneration

Interventions

DRUG

LHA510 ophthalmic suspension

DRUG

LHA510 vehicle

Inactive ingredients used as a placebo comparator

DRUG

Ranibizumab ophthalmic solution

For intravitreal (IVT) injection

Trial Locations (1)

76134

Contact Alcon Call Center for Trial Locations, Fort Worth

All Listed Sponsors

lead

Alcon, a Novartis Company

INDUSTRY

NCT02355028 - LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration | Biotech Hunter | Biotech Hunter